istock-485508035-alexandrumagurean

alexandrumagurean / iStockphoto.com

13 September 2018Big Pharma

LSIPR webinar: HGF delves into personalised healthcare patents

Personalised healthcare is a rapidly developing field, not just because of medical advancements, but also because the criteria necessary to secure second medical use patents has similarly evolved over the years, an industry webinar heard.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSIPR webinar: HGF on doctrine of equivalence evolution

16 October 2018 The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

22 March 2018 Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.

More on this story

LSIPR webinar: HGF on doctrine of equivalence evolution

16 October 2018 The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

22 March 2018 Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.

More on this story

LSIPR webinar: HGF on doctrine of equivalence evolution

16 October 2018 The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

22 March 2018 Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.

More features

UPC hands rare default win to Insulet, bans insulin pump in EU

GSK loses appeal over purple inhaler TM in Europe

Astellas defends Xtandi patent as court rejects generics’ appeal

Jury sides with Allergan in $56M Botox tech feud

Novartis fails latest bid to block Entresto copies

BMS blocks biosimilar version of blockbuster cancer drug in India

WATCH: Protecting life science innovations involving big data, AI and machine learning

AbbVie blocks Humira antitrust suit